Literature DB >> 22357833

Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.

Yuelian Sun1, Jakob Christensen, Anders Hviid, Jiong Li, Peter Vedsted, Jørn Olsen, Mogens Vestergaard.   

Abstract

CONTEXT: Vaccination with whole-cell pertussis vaccine carries an increased risk of febrile seizures, but whether this risk applies to the acellular pertussis vaccine is not known. In Denmark, acellular pertussis vaccine has been included in the combined diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine since September 2002.
OBJECTIVE: To estimate the risk of febrile seizures and epilepsy after DTaP-IPV-Hib vaccination given at 3, 5, and 12 months. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of 378,834 children who were born in Denmark between January 1, 2003, and December 31, 2008, and followed up through December 31, 2009; and a self-controlled case series (SCCS) study based on children with febrile seizures during follow-up of the cohort. MAIN OUTCOME MEASURES: Hazard ratio (HR) of febrile seizures within 0 to 7 days (0, 1-3, and 4-7 days) after each vaccination and HR of epilepsy after first vaccination in the cohort study. Relative incidence of febrile seizures within 0 to 7 days (0, 1-3, and 4-7 days) after each vaccination in the SCCS study.
RESULTS: A total of 7811 children were diagnosed with febrile seizures before 18 months, of whom 17 were diagnosed within 0 to 7 days after the first (incidence rate, 0.8 per 100,000 person-days), 32 children after the second (1.3 per 100,000 person-days), and 201 children after the third (8.5 per 100,000 person-days) vaccinations. Overall, children did not have higher risks of febrile seizures during the 0 to 7 days after the 3 vaccinations vs a reference cohort of children who were not within 0 to 7 days of vaccination. However, a higher risk of febrile seizures was found on the day of the first (HR, 6.02; 95% CI, 2.86-12.65) and on the day of the second (HR, 3.94; 95% CI, 2.18-7.10), but not on the day of the third vaccination (HR, 1.07; 95% CI, 0.73-1.57) vs the reference cohort. On the day of vaccination, 9 children were diagnosed with febrile seizures after the first (5.5 per 100,000 person-days), 12 children after the second (5.7 per 100,000 person-days), and 27 children after the third (13.1 per 100,000 person-days) vaccinations. The relative incidences from the SCCS study design were similar to the cohort study design. Within 7 years of follow-up, 131 unvaccinated children and 2117 vaccinated children were diagnosed with epilepsy, 813 diagnosed between 3 and 15 months (2.4 per 1000 person-years) and 1304 diagnosed later in life (1.3 per 1000 person-years). After vaccination, children had a lower risk of epilepsy between 3 and 15 months (HR, 0.63; 95% CI, 0.50-0.79) and a similar risk for epilepsy later in life (HR, 1.01; 95% CI, 0.66-1.56) vs unvaccinated children.
CONCLUSIONS: DTaP-IPV-Hib vaccination was associated with an increased risk of febrile seizures on the day of the first 2 vaccinations given at 3 and 5 months, although the absolute risk was small. Vaccination with DTaP-IPV-Hib was not associated with an increased risk of epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357833     DOI: 10.1001/jama.2012.165

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

1. 

Authors:  Nicholas Monfries; Ran D Goldman
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

2.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

3.  Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event.

Authors:  Shirley V Wang; Kristina Stefanini; Edwin Lewis; Sophia R Newcomer; Bruce Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric Weintraub; Martin Kulldorff
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

4.  Prophylactic antipyretics for prevention of febrile seizures following vaccination.

Authors:  Nicholas Monfries; Ran D Goldman
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

5.  Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine.

Authors:  Huakun Lv; Xuejiao Pan; Hui Liang; Ying Wang; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-09-07       Impact factor: 4.526

6.  Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample.

Authors:  Stanley Xu; Christina L Clarke; Sophia R Newcomer; Matthew F Daley; Jason M Glanz
Journal:  Biom J       Date:  2018-05-16       Impact factor: 2.207

7.  Prevalence of recent immunisation in children with febrile convulsions.

Authors:  Leya Motala; Guy D Eslick
Journal:  World J Clin Pediatr       Date:  2016-08-08

8.  Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines.

Authors:  Pedro L Moro; Silvia Perez-Vilar; Paige Lewis; Marthe Bryant-Genevier; Hajime Kamiya; Maria Cano
Journal:  Pediatrics       Date:  2018-06-04       Impact factor: 7.124

9.  Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.

Authors:  Thomas A Rasmussen; Martin R S Jørgensen; Stephanie Bjerrum; Søren Jensen-Fangel; Henrik Støvring; Lars Østergaard; Ole S Søgaard
Journal:  BMJ       Date:  2012-09-17

10.  Prevalence of SCN1A-related dravet syndrome among children reported with seizures following vaccination: a population-based ten-year cohort study.

Authors:  Nienke E Verbeek; Nicoline A T van der Maas; Floor E Jansen; Marjan J A van Kempen; Dick Lindhout; Eva H Brilstra
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.